BS_N4B1SZZH
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 82.95006570302233
- age_years
- 12.4
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.555
- PANCREAS_BETA_CELLS+0.501
- G2M_CHECKPOINT+0.495
- MYC_TARGETS_V2+0.373
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.277
- MYC_TARGETS_V1+0.255
- KRAS_SIGNALING_DN+0.227
- SPERMATOGENESIS+0.192
- ANGIOGENESIS+0.163
- KRAS_SIGNALING_UP+0.100
Top 10 suppressed
- NOTCH_SIGNALING-0.482
- OXIDATIVE_PHOSPHORYLATION-0.455
- PROTEIN_SECRETION-0.436
- ADIPOGENESIS-0.432
- INTERFERON_ALPHA_RESPONSE-0.424
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.384
- INTERFERON_GAMMA_RESPONSE-0.327
- TGF_BETA_SIGNALING-0.307
- FATTY_ACID_METABOLISM-0.304
- BILE_ACID_METABOLISM-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_XG0DBWVT | high-grade glioma | — | 0.821 |
| 2 | MNG1001 | — | — | 0.817 |
| 3 | BS_JVW2JJ39 | high-grade glioma | — | 0.800 |
| 4 | BS_JT82QGXF | medulloblastoma | — | 0.757 |
| 5 | BS_AHEFXG7W | medulloblastoma | — | 0.756 |
| 6 | BS_JR5ATB7G | medulloblastoma | — | 0.754 |
| 7 | TCGA-21-1081-01A-01R-0692-07 | — | cohortSQ1 | 0.746 |
| 8 | 266352 | EPN | EPN Tumor | 0.744 |
| 9 | 7107da6d-83c9-47af-bbf5-c677e50dcfad | — | — | 0.743 |
| 10 | BS_J1AB8PMA | medulloblastoma | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.555 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.501 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.495 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.277 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.255 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.227 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.192 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.163 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.088 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.086 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.079 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.066 | Inavolisib | — uncovered |
| MYOGENESIS | 0.056 | Inavolisib | — uncovered |
| COAGULATION | 0.032 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.031 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.026 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.021 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.006 | Idelalisib | — uncovered |